Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Pipeline Review, H1 2016

  • ID: 3802815
  • Report
  • 48 pages
  • Global Markets Direct
1 of 5
Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Pipeline Review, H1 2016

Summary

‘Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Pipeline Review, H1 2016’, provides in depth analysis on Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) targeted pipeline therapeutics.

The report provides comprehensive information on the Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22)
- The report reviews Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5
List of Tables

List of Figures

Introduction

Report Coverage

Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) Overview

Therapeutics Development

Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Products under Development by Stage of Development

Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Products under Development by Therapy Area

Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Products under Development by Indication

Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Products under Development by Companies

Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Products under Development by Universities/Institutes

Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Companies Involved in Therapeutics Development

Cyclacel Pharmaceuticals, Inc.

Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Drug Profiles

CT-526 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CYC-065 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sapacitabine + seliciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDK1, CDK5 and GSK3b for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit CDK5 for CNS and Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TFP-5 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Dormant Projects

Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) - Featured News & Press Releases

Jun 06, 2016: Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO

May 19, 2016: Cyclacel’s Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 18, 2016: Cyclacel’s Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors

Dec 14, 2015: Molecular Basis for Development of Cyclacel’s CYC065 CDK2/9 Inhibitor in Triple-Negative Breast Cancer Presented at San Antonio Breast Cancer Symposium

Nov 23, 2015: CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models

Nov 09, 2015: Mechanistic Rationale for CYC065, Cyclacel's CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference

Oct 26, 2015: Data to be Presented on CYC065, Cyclacel's CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference

Oct 22, 2015: Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors

Sep 17, 2015: Cyclacel Presents Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias and Lymphomas

Apr 20, 2015: Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential and Synergy With Other Anti-Cancer Compounds

Mar 20, 2015: Cyclacel's CYC065 Featured in Presentations at the American Association for Cancer Research Annual Meeting 2015

Sep 18, 2014: Cyclacel's CYC065 CDK Inhibitor Demonstrates Therapeutic Potential in Acute Leukemias With Mixed Lineage Leukemia (MLL) Rearrangements

Sep 10, 2014: Cyclacel Announces Abstract Selected for Presentation at Society of Hematologic Oncology Annual Meeting

Apr 09, 2013: Cyclacel Pharma Presents Data On Combination Potential Of Sapacitabine And Seliciclib At AACR Annual Meeting 2013

Apr 07, 2013: New Drug Combination Shows Efficacy Against Incurable Solid Tumors And BRCA mutations, Study Finds

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 48List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016

Dormant Projects, H1 2016 33List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) pipeline Target constitutes close to 6 molecules. Out of which approximately 3 molecules are developed by Companies and remaining by the Universities/Institutes. The author's latest report Cyclin-Dependent Kinase 5 - Pipeline Review, H1 2016, outlays comprehensive information on the Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) Cell division protein kinase 5 is an enzyme encoded by the CDK5 gene. It does not directly control cell cycle regulation. Instead it functions in diverse processes such as synaptic plasticity and neuronal migration through phosphorylation of proteins required for cytoskeletal organization, endocytosis and exocytosis, and apoptosis. Dysregulation of this enzyme is involved in several neurodegenerative diseases including Alzheimer's disease and invasive cancers. The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Cyclin-Dependent Kinase 5 (Serine/Threonine-Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or EC 2.7.11.22) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
Cyclacel Pharmaceuticals, Inc
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll